Abstract
Cardiovascular diseases are the leading cause of death worldwide. Research in the last two decades has emphasized the inflammatory process as a key component in the pathogenesis of many of them. The Interleukin-1 family is a pivotal element of inflammation and has been well studied as a therapeutic target in various inflammatory states. Recent trials have explored the effect of Interleukin-1 blockade in cardiovascular diseases and initial evidence of the relevance of such treatment in this field of medicine accumulate. This review will describe the role of Interleukin-1 in heart diseases and the potential therapeutic effect of its blockade in such diseases.
Highlights
Cardiovascular diseases are the leading cause of death worldwide
IL-1 receptor blockade was found highly effective in several case reports presenting patients with adult-onset Still’s disease (AOSD) and secondary fulminant myocarditis, which was successfully treated with anakinra [82]
Studies regarding direct IL-1 blockade in this setup are still lacking. It seems that inflammation plays a role in the pathogenesis of many heart diseases, with IL-1 being one of the main mediators in this inflammatory process
Summary
Cardiovascular diseases are the leading cause of death worldwide. Research in the last two decades has emphasized the inflammatory process as a key component in the pathogenesis of many of them. The Interleukin-1 family is a pivotal element of inflammation and has been well studied as a therapeutic target in various inflammatory states. Recent trials have explored the effect of Interleukin-1 blockade in cardiovascular diseases and initial evidence of the relevance of such treatment in this field of medicine accumulate. This review will describe the role of Interleukin-1 in heart diseases and the potential therapeutic effect of its blockade in such diseases
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have